Huntington National Bank Has $125.30 Million Holdings in AbbVie Inc. $ABBV

Huntington National Bank grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 8.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 675,008 shares of the company’s stock after purchasing an additional 53,577 shares during the period. AbbVie comprises 0.8% of Huntington National Bank’s holdings, making the stock its 29th largest holding. Huntington National Bank’s holdings in AbbVie were worth $125,295,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of AbbVie by 1.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,059,568 shares of the company’s stock worth $1,060,081,000 after buying an additional 95,756 shares during the last quarter. Capital Advisors Inc. OK lifted its position in shares of AbbVie by 3.5% during the 1st quarter. Capital Advisors Inc. OK now owns 346,804 shares of the company’s stock worth $72,662,000 after buying an additional 11,793 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its position in shares of AbbVie by 15.5% during the 1st quarter. TD Private Client Wealth LLC now owns 78,953 shares of the company’s stock worth $16,542,000 after buying an additional 10,609 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Evercore ISI upped their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. HSBC set a $225.00 price objective on AbbVie in a research report on Thursday, October 2nd. Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Finally, Morgan Stanley increased their target price on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $237.85.

AbbVie Price Performance

Shares of ABBV opened at $212.04 on Tuesday. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company has a market capitalization of $374.58 billion, a price-to-earnings ratio of 100.97, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The business has a 50-day moving average of $222.51 and a 200-day moving average of $201.42.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the company earned $3.00 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.